Head-to-head evidence
infliximab-abda (Renflexis) vs infliximab-dyyb (Zymfentra)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
infliximab-abda (Renflexis)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT04205643 · Phase 3 · completed
The trial was randomized, quadruple-blind, and placebo-controlled, with 548 participants enrolled and 438 participants included in the reported maintenance analysis. The hard clinical primary endpoint—clinical remission by the modified Mayo score at week 54—was met, with 127 of 294 participants receiving CT-P13 versus 30 of 144 receiving placebo (p<0.0001).
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
infliximab-abda (Renflexis)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT03945019 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.
Next expected readout: December 2026 · NCT06064864 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: infliximab-abda (Renflexis)'s landscape · infliximab-dyyb (Zymfentra)'s landscape